Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$50.35 ▲ +0.13
(+0.26%)
MKT CAP: $10.35B • VOL: 3.57M
52W L $33 52W H $58
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$42
MEDIAN
$56
MEAN
$57
HIGH
$68
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE QGEN TAPE
QGEN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $60.92 | $57.90 | 2025-02-14 | $45.82 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $63.44 | $59.41 | 2025-02-06 | $47.33 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $57.40 | $55.39 | 2025-01-29 | $48.34 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $51.36 | — | 2025-01-17 | $49.34 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $44.31 | $47.83 | 2025-01-09 | $44.81 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $59.92 | $52.36 | 2024-12-18 | $43.80 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $48.84 | $50.85 | 2024-12-04 | $46.83 | -4.3% | 48% | C |